
|Videos|December 11, 2021
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection
Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Advertisement
Pharmacy Times interviewed Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, on her presentation at the American Society of Health-System Pharmacists 2021 Midyear Clinical Meeting on whether the power of the microbiome can be unlocked to break the cycle of recurrent Clostridioides difficile (C. diff) infection.
During the interview, Chopra discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
5




























































































































